Nanomedicines : design delivery and detection Nanomedicines and nanopharmacology is a rapidly developing and evolving field with new techniques and applications under constant development. This book will provide an overview of the chemistry of nanocarrier design and the considerations that need to be made when developing a nanomedicine. Providing an understanding of the relationship of nanocarrier drug and targetting moieties and physico chemical properties this title will provide an accurate and current representation of the field by addressing the promises prospects and pitfalls of nanomedicine. Covering a wide range of areas in detail this book will provide an excellent companion for medicinal chemists pharmacologists and biochemists working in industry or academia 4.2 External Magnetic Device4.3 Labeling Mesenchymal Stem Cells with Supraparamagnetic Iron Oxide; 4.4 Adhesion of m MSCs to the Tissue Injured Site; 4.5 Animal Studies; 4.6 Conclusion; Acknowledgments; References; 5.1 Introduction; 5.2 Theranostic Carrier Materials; 5.3 Theranostics and Imaging; 5.4 Conclusions; References; 6.1 Introduction; 6.2 Imaging for In vivo Evaluation of the Spatio temporal Distribution Characteristics of Nanomedicines; 6.3 Use of Imaging to Understand and Optimize Nanomedicine Performance; 6.4 Clinical Experience and Future Considerations; References Chapter 6 The Role of Imaging in Nanomedicine Development and Clinical TranslationChapter 7 Anticancer Agent Incorporating Polymeric Micelles: from Bench to Bedside; Chapter 8 Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101; Chapter 9 Nanodelivery Strategies in Breast Cancer Chemotherapy; Chapter 10 Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurement; Chapter 11 Nanomedicine: Promises and Challenges; Chapter 12 The Challenge of Regulating Nanomedicine: Key Issues Cover; Contents; Preface; Chapter 1 Design Considerations for Properties of Nanocarriers on Disposition and Efficiency of Drug and Gene Delivery; Chapter 2 Targeting Cyclins and Cyclin dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapy; Chapter 3 Nanoparticle Carriers to Overcome Biological Barriers to siRNA Delivery; Chapter 4 Magnetic Targeting as a Vehicle for the Delivery of Nanomedicines; Chapter 5 The Development of Theranostics Imaging Considerations and Targeted Drug Delivery 7.1 Introduction7.2 Anticancer Agents Incorporating Micelles under Clinical Evaluation; 7.3 Verification of the EPR Effect using Imaging Mass Spectrometry; 7.4 Discussion and Conclusion; References; 8.1 Introduction; 8.2 Topoisomerase 1 Inhibitors; 8.3 Hypoxia Inducible Factor 1 Inhibitors; 8.4 Cancer Stem Cells; 8.5 Combination Therapy; 8.6 CRLX101; 8.7 Conclusion; References; 9.1 Introduction; 9.2 Nanocarriers for Drug Delivery to Solid Tumors; 9.3 Doxil® The First FDA approved Nano drug; 9.4 Taxane based Nanodelivery (Abraxane® and Genexol PM®); 9.5 CrEL free Formulations of PTX Chapter 13 Doxil® the First FDA approved Nano drug: from Basics via CMC Cell Culture and Animal Studies to Clinical UseSubject Index; References; 1.1 Introduction; 1.2 Types of Nanocarriers Nanoparticles; 1.3 Physicochemical Factors that Affect Nanoparticle Efficiency; 1.4 Conclusions; References; 2.1 Introduction; 2.2 The Cell Cycle; 2.3 Deregulation of the Cell Cycle in Cancer; 2.4 RNA Interference; 2.5 Concluding Remarks; Acknowledgments; References; 3.1 Introduction; 3.2 Extracellular Barriers; 3.3 Cellular Barriers; 3.4 siRNA Delivery Systems; References; 4.1 Introduction